Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.
Cancer Res
; 63(10): 2470-6, 2003 May 15.
Article
em En
| MEDLINE
| ID: mdl-12750268
ABSTRACT
Targeted adoptive immunotherapy is an attractive option for prostate cancer given its accessible primary location, the presence of specific tissue and tumor antigens, and the acceptability of collateral destruction of healthy prostrate tissue. The "T-body" approach, which uses genetically programmed, patient-derived lymphocytes transfected with chimeric receptor genes, combines the effector functions of T lymphocytes and natural killer cells with the ability of antibodies to recognize predefined surface antigens with high specificity and in a non-MHC restricted manner. We evaluated the therapeutic efficacy of anti-erbB2 chimeric receptor-bearing human lymphocytes on human prostate cancer xenografts in a SCID mouse model. Local delivery of erbB2-specific T bodies to well-established s.c. and orthotopic tumors, together with systemic administration of interleukin-2, resulted in retardation of both tumor growth and prostate-specific antigen secretion, prolongation of survival, and complete tumor elimination in a significant number of mice. These preclinical studies demonstrate the therapeutic potential of the T-body approach for locally advanced or recurrent prostate cancer as an adjunct to, or after, conventional therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Proteínas Recombinantes de Fusão
/
Linfócitos
/
Terapia Genética
/
Adenocarcinoma
/
Imunoterapia Adotiva
/
Receptor ErbB-2
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2003
Tipo de documento:
Article